XII Results Neutral

NUMERAL LIMITED - Update on Healthcare and Biotech Strategy, Investments and the Finalisation of Audited Results

Numeral LimitedJul 9, 2026

Free preview

What this filing means

Numeral has delayed its 28 February 2026 audited results to on or about 15 July, blaming the accounting treatment of two investments — Longevity and Isopharm — where the board could not get usable information from the founder and has since settled to recover its money. The rest of the update outlines strategic progress: Boost & Recovery's Kyalami flagship is targeted within 60 days, Cryo-Save crossed to 51% control, and WestMed is a new healthcare investment — but no financial figures are discl…

Bull case

Boost & Recovery's Kyalami flagship sits on a firm 60-day completion clock, with Sandton City and Camps Bay already mapped — a concrete near-term revenue catalyst.
Cryo-Save crossed to 51% control and is described as the biotech cornerstone enjoying 'solid growth', consolidating earnings into Numeral.

Bear case

Audited results are targeted only for 15 July 2026 — roughly five months after year-end — leaving revenue, cash, and debt position completely unverified in this update.

View original SENS announcement

AI-generated summary by SENS-AI, based on the original JSE SENS filing.

Unlock the full analysis

Free during launch. Sign in to read the complete breakdown.

Full bull / bear breakdown
Decision framework
Citations & sources
Price autopsy

More on Numeral Limited

Numeral Limited (XII) share price All Numeral Limited SENS announcements

Related filings

Other Results

PHP
PRIMARY HEALTH PROPERTIES PLC - Statement regarding press speculation
Jun 24, 2026